Summary & Overview
HCPCS J3399: Onasemnogene Abeparvovec-xioi Injection, Single-Dose Gene Therapy
HCPCS Level II code J3399 represents the per-treatment injection of onasemnogene abeparvovec-xioi (up to 5x10^15 vector genomes), a single-dose systemic gene therapy. This code matters nationally because it captures billing for a high-cost, specialty biologic therapy used in rare genetic conditions and has implications for coverage policy, prior authorization, and site-of-care decisions. Payers commonly engaged in managing access and reimbursement for this therapy include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare.
Readers will find benchmarks and practical context for J3399, including typical service settings, clinical background on single-dose gene vector administration, and an overview of payer involvement in coverage and reimbursement pathways. The publication highlights policy considerations relevant to high-cost gene therapies, such as billing clarity, one-time administration coding, and implications for inpatient versus outpatient site designation. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J3399 describes the injection of onasemnogene abeparvovec-xioi, billed per treatment for a dose of up to 5x10^15 vector genomes. This entry represents a high-cost, one-time gene therapy administration intended to deliver a functional copy of a gene via viral vector.
-
Service type: Gene therapy injection / single-dose systemic gene vector administration
-
Typical site of service: Hospital inpatient or outpatient infusion/operating room setting, including specialized infusion centers or ambulatory surgical centers equipped for complex biologic administrations.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A pediatric patient with a genetically confirmed diagnosis of spinal muscular atrophy (SMA) type 1 is scheduled for a single-dose intravenous gene replacement therapy using onasemnogene abeparvovec-xioi. The clinical workflow begins with multidisciplinary pre-treatment evaluation: neurology confirms SMA with biallelic SMN1 deletion, baseline laboratory testing (CBC, liver panel, coagulation studies), and anti-AAV9 antibody titer assessment. A weight-based dose calculation is performed to confirm the total vector genomes do not exceed the single-treatment vial limit described by J3399. Pre-medications (for example, corticosteroids) are prescribed to mitigate transaminase elevations and immune responses, and caregivers receive education on monitoring and emergency contacts.
On the day of service the child is admitted to an outpatient infusion center or inpatient pediatric unit depending on institutional protocol and clinical status. An infusion nurse and pediatric anesthesiology or sedation team establish IV access, verify patient identity and informed consent, and administer the intravenous infusion over the recommended time with continuous monitoring of vital signs. Liver enzymes and platelets are monitored post-infusion; corticosteroid taper is followed per protocol. Follow-up visits include liver function monitoring, clinical neurology assessments, and documentation of adverse events. Billing uses J3399 for the onasemnogene abeparvovec-xioi administration, with potential addition of appropriate modifiers to indicate unusual circumstances such as distinct procedural services, service reductions, or anesthesia involvement.
Coding Specifications
| Modifier | Description | When to Use |
|---|